Perseus Proteomics Inc. [4882.T]
TOKYO, Jun 30 (Pulse News Wire) – Perseus Proteomics Inc. (4882.T) amended part of its previously disclosed business plan and growth potential statement dated June 25, 2026.
The amendment was made due to errors identified in the description of key personnel and their backgrounds. The revised document highlights ongoing activities related to clinical development and antibody research support services. As of March 31, 2026, the company's PPMX-T003 trial had extended its testing period until March 31, 2027, with Osaka University Hospital joining as a new trial site. Additionally, the company secured funding of ¥100 million from AMED’s drug development support program.
In antibody research support, the company reported six consecutive quarters of revenue growth, launching screening and production services using camelid antibody libraries. It also noted plans to expand its pipeline and platform business through partnerships and technological advancements. Perseus Proteomics maintains capital of ¥500 million and employs 35 staff members. The next update on the business plan and growth potential is scheduled for June 2027.
🟡 Confidence: Standard AI-translated content.